Construction and immunogenicity analysis of a recombinant baculovirus targeting the N protein of SARS-CoV-2.

IF 2.1 4区生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biotechnology Letters Pub Date : 2025-04-16 DOI:10.1007/s10529-025-03576-6

Bohan Yu, Xiaoli Mo, Li Sui, Yujia Fang, Xudong Tang, Ping Qian

引用次数: 0

Abstract

Objectives: This study aimed to construct recombinant baculoviruses capable of expressing the nucleocapsid N protein of SARS-CoV-2 and to assess the effects of co-administration with sodium butyrate on its expression and immunogenicity.

Results: The recombinant BmNPV expressed green fluorescent protein in BmN cells and N protein in mammalian cells. The addition of sodium butyrate significantly enhanced the expression of N protein in HEK293T cells. Following intramuscular injection of recombinant BmNPV into mice, specific antibodies against the N protein were detectedon day 7, 21, and 35. Co-administration with sodium butyrate (1000 mg/kg body weight) significantly enhanced the immunogenicity of the recombinant virus.

Conclusions: Recombinant BmNPV expressing the SARS-CoV2 N protein successfully inducedthe anti-N immunogenicity in mice, providing a solid foundationfor the development of novel subunit vaccines against SARS-CoV-2.

查看原文本刊更多论文

靶向SARS-CoV-2 N蛋白重组杆状病毒的构建及免疫原性分析。

目的：构建能够表达SARS-CoV-2核衣壳N蛋白的重组杆状病毒，并评价与丁酸钠共给药对其表达和免疫原性的影响。结果：重组BmNPV在BmN细胞中表达绿色荧光蛋白，在哺乳动物细胞中表达N蛋白。添加丁酸钠可显著增强HEK293T细胞中N蛋白的表达。在小鼠肌肉注射重组BmNPV后，在第7、21和35天检测到针对N蛋白的特异性抗体。与丁酸钠（1000 mg/kg体重）共给药可显著增强重组病毒的免疫原性。结论：表达SARS-CoV2 N蛋白的重组BmNPV成功诱导小鼠抗N免疫原性，为研制新型SARS-CoV-2亚单位疫苗提供了坚实的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Letters 工程技术-生物工程与应用微生物

CiteScore

5.90

自引率

3.70%

发文量

108

审稿时长

1.2 months

期刊介绍： Biotechnology Letters is the world’s leading rapid-publication primary journal dedicated to biotechnology as a whole – that is to topics relating to actual or potential applications of biological reactions affected by microbial, plant or animal cells and biocatalysts derived from them. All relevant aspects of molecular biology, genetics and cell biochemistry, of process and reactor design, of pre- and post-treatment steps, and of manufacturing or service operations are therefore included. Contributions from industrial and academic laboratories are equally welcome. We also welcome contributions covering biotechnological aspects of regenerative medicine and biomaterials and also cancer biotechnology. Criteria for the acceptance of papers relate to our aim of publishing useful and informative results that will be of value to other workers in related fields. The emphasis is very much on novelty and immediacy in order to justify rapid publication of authors’ results. It should be noted, however, that we do not normally publish papers (but this is not absolute) that deal with unidentified consortia of microorganisms (e.g. as in activated sludge) as these results may not be easily reproducible in other laboratories. Papers describing the isolation and identification of microorganisms are not regarded as appropriate but such information can be appended as supporting information to a paper. Papers dealing with simple process development are usually considered to lack sufficient novelty or interest to warrant publication.